Bis-(hydroxyamino)triazines: Highly stable hydroxylamine-based ligands for iron(III) cations

Chemical Communications

Volumn , Issue 42, 2005, Pages 5319-5321

  Gun, Jenny ^a   Ekeltchik, Irina ^a   Lev, Ovadia ^a   Shelko, Rimma ^a   Melman, Artem ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CATION; DEFEROXAMINE; EDETIC ACID; HYDROXYLAMINE; IRON CHELATE; LIGAND; TRIAZINE DERIVATIVE;

ARTICLE; BINDING AFFINITY; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; MOLECULAR STABILITY; STRUCTURE ANALYSIS;

EID: 27944431588     PISSN: 13597345     EISSN: None     Source Type: Journal    
DOI: 10.1039/b508138f     Document Type: Article

References (30)

1. Z. D. Liu and R. C. Hider, Coord. Chem. Rev., 2002, 232, 151-171.
2. See reviews: (a) Z. D. Liu and R. C. Hider, Med. Res. Rev., 2002, 22, 26-64;
3. (b) G. Faa and G. Crisponi, Coord. Chem. Rev., 1999, 184, 291-310;
4. T. B. Chaston and D. R. Richardson, Am. J. Hematol., 2003, 73, 200-210;
5. D. R. Richardson and P. Ponka, Am. J. Hematol., 1998, 58, 299-305.
6. R. D. Hancock and A. E. Martell, Chem. Rev., 1989, 89, 1875-1914.
7. W. Stumm and J. J. Morgan, Aquatic Chemistry, 3rd edn, ch. 10, pp 646-648 and ch. 12.5, pp 744-748, J. Wiley & Sons, NY, 1996.
8. J. Almog and B. Glattstein, J. Forensic Sci., 1997, 42, 993-996.
9. B. P. Esposito, S. Epsztejn, W. Breuer and Z. I. Cabantchik, Anal. Biochem., 2002, 304, 1-18.
10. (a) M. Costas, K. Chen and L. Que, Coord. Chem. Rev., 2000, 200, 517-544;
11. (b) S. Kanemasa, Y. Oderaotoshi, S. Sakaguchi, H. Yamamoto, J. Tanaka, E. Wada and D. P. Curran, J. Am. Chem. Soc., 1998, 120, 3074-3088.
12. For example J. Y. Chen, O. Ikeda, T. Hatasa, A. Kitajima, M. Miyake and A. Yamatodani, Electrochem. Commun., 1999, 1, 274-277.
13. See reviews: (a) L. D. Horwitz and E. A. Rosenthal, Vasc. Med., 1999, 4, 93-99;
14. (b) J. L. Sullivan, J. Lab. Clin. Med., 2004, 144, 280-284.
15. C. R. J. C. Newton, T. T. Hien and N. White, J. Neurol. Nerurosurg. Psychiatry, 2000, 69, 433-441.
16. R. Baliga, N. Ueda, P. D. Walker and S. V. Shah, Drug Metabol. Rev., 1999, 31, 971-997.
17. E. D. Weinberg, Eur. J. Cancer Prevent., 1996, 5, 19-36.
18. (a) E. C. Hirsch and B. A. Faucheux, Movement Disorders, 1998, 13, 39-45, Suppl. 1;
19. (b) W. Linert, E. Herlinger, R. F. Jameson, E. Kienzl, K. Jellinger and M. B. H. Youdim, Biochim. Biophys. Acta, 1996, 1316, 160-168.
20. M. A. Smith, P. L. R. Harris, L. M. Sayre and G. Perry, Proc. Natl. Acad. Sci. USA, 1997, 94, 9866-9868.
21. (a) M. K. Mahanthappa, A. P. Cole and R. M. Waymouth, Organometallics, 2004, 23, 1405-1410;
22. (b) C. Lustig and N. W. Mitzel, Angew. Chem., Int. Ed., 2001, 40, 4390-4392;
23. R. Reichenbach-Klinke, M. Zabel and B. Koenig, Dalton Trans., 2003, 141-145.
24. Experimental procedures and full characterization are contained in the ESI†.
25. Several hydroxyamino 1,3,5-triazines synthesized previously: J. T. Shaw, E. R. Nicottra and R. K. Madison, J. Org. Chem., 1962, 27, 4054-4056.
26. A. R. Katritzky, I. Ghiviriga, P. J. Steel and D. C. Oniciu, J. Chem. Soc., Perkin Trans 2, 1996, 443-447.
27. 2 = 0.1175, 11703 independent reflections [2Θ = 54°] and 729 parameters. CCDC 264501. See http://dx.doi.org/10.1039/b508138f for crystallographic data in CIF or other electronic format.
28. A. Winston, J. Pharmacol. Exp. Ther., 1985, 232, 644-649.
29. J. C. Barton, Curr. Opin. Invest. Drug, 2005, 6, 327-335.
30. A. J. Bard and L. F. Faulkner, Electrochemical Methods, 2nd edn, J. Wiley and Sons, NY 2001.